Data & Analytics Platforms: IQVIA vs Komodo Health vs Definitive Healthcare vs ConcertAI | Rx Almanac
Head-to-head comparison of the four dominant data and analytics platforms for pharma commercial operations. Represents the ecosystem question facing procurement teams: legacy incumbent (IQVIA) vers...
Overview
The healthcare data and analytics market has bifurcated into two distinct value propositions: commercial intelligence (prescription audits, sales force targeting, market sizing) and research-grade real-world evidence (RWE) powering HEOR, regulatory submissions, and clinical trial design. These two use cases once required entirely different vendor relationships. They increasingly do not.
The global healthcare data and analytics market was valued at approximately $30 billion in 2024 and is projected to reach $74 billion by 2031 at a 15.2% CAGR. Growth is driven by payers demanding real-world outcomes evidence, regulators accepting RWE as supplementary to trial data, and commercial teams requiring AI-guided targeting over mass rep deployment.
Competitor Profiles
IQVIA
Emerged from the 2016 merger of IMS Health and Quintiles. $15.4 billion total revenue (2024), TAS segment $6.16 billion (+5.1% YoY). ~88,000 employees. Processes over 100 billion data points annually. Data moat includes nearly 4 billion prescription claims/year (LRx), 191 million patients (medical/institutional claims), OneKey reference dataset (9 million HCPs, 700,000 HCOs), and MIDAS across 77 countries. Technology: Orchestrated Analytics (AI-driven KPI tracking, territory optimization, next-best-action), OCE for integrated commercial workflows, E360 for RWE. Acquired WhizAI (May 2025) for conversational AI analytics.
Komodo Health
Founded 2014, San Francisco. Built Healthcare Map — a unified patient-level map from source claims covering 330+ million patients with 16 million clinical encounters added daily and 160 million closed, linkable lives. Total funding $514 million including $220M Series E (2021, $3.3B valuation). Revenue ~$200M (2023). 200+ life sciences and healthcare organizations, 19 of top 20 biopharma (as of 2020). Launched Marmot AI (August 2025) — healthcare-native AI engine converting complex analytical questions from weeks to minutes. Launched Healthcare Map on Snowflake Marketplace (October 2025).
Definitive Healthcare
Built franchise around provider intelligence: hospital profiles, IDN structures, facility-level claims. Atlas Dataset: 15 million HCPs, 301,000 organizations, 8 billion+ claims covering 330 million patients. Acquired Populi (2024) adding 180 billion claims/EHR/lab/consumer records. Went public on NASDAQ (2021), taken private by Advent International (2024). Under financial pressure: 2025 revenue $241.5M (down 4% YoY), net dollar retention 85%, 2026 projected $220-226M (further 6-9% decline). ~782 employees, ~2,500 customers.
ConcertAI
Founded 2018, oncology-focused RWE and AI company. Acquired ASCO’s CancerLinQ (December 2023) — 5.5 million multi-modal oncology records forming CARAai Clinical RWD Cloud. Raised $230M+ (Series C, $1.9B valuation in 2022). Revenue ~$200M (FY2023) with ~30% ARR growth, 72% recurring revenue, mid-teens EBITDA margins (profitable). Works with 75% of top 30 life sciences organizations and 2,000+ healthcare provider sites. CARAai platform includes oncology-tuned LLMs, NLP, predictive AI, digital pathology. Launched Accelerated Clinical Trials (ACT) platform (February 2026). Integrated data with Foundation Medicine (January 2026) for clinico-genomic dataset of nearly 500K cancer patients.
Head-to-Head Comparison
Data Assets
| Dimension | IQVIA | Komodo Health | Definitive Healthcare | ConcertAI |
|---|---|---|---|---|
| Rx/claims coverage | 93% of outpatient Rx; 4B+ claims/year | 330M+ patients; all-payer claims | 8B+ all-payer claims; 330M patients | Oncology EMR-focused, not claims |
| EHR/EMR | Partnerships; not core | MapEnhance includes EHR linkage | 180B+ records via Populi | Core: 5.5M+ multi-modal oncology EMR |
| Prescription data | Deepest: Xponent (93% retail + mail/LTC) | Claims-derived Rx; longitudinal | Atlas Rx Claims (paid, rejected, reversed) | Minimal direct Rx audit |
| Patient coverage | 191M (medical/institutional); 260M+ (Rx) | 330M+ journeys; 160M closed linkable lives | 330M patients | 5.5M oncology/hematology (curated) |
| HCP/HCO reference | OneKey: 9M HCPs, 700K HCOs | Claims-derived HCP profiling | 15M HCPs, 301K orgs (strongest institutional) | 2,000+ oncology provider sites |
| Global reach | 77 countries (MIDAS); only true global platform | U.S.-centric | U.S.-centric | U.S.-centric; expanding |
| Data freshness | Daily Rx; monthly MIDAS | Near real-time (16M encounters/day) | Continuously updated | Near real-time for oncology EMR |
| Genomic/molecular | Limited | MapEnhance includes rare disease linkage | Limited | Deep: Foundation Medicine, Caris, NeoGenomics, Guardant |
Bottom line on data: IQVIA has the longest history and deepest prescriber-level Rx data — Xponent is the industry standard competitors cannot easily replicate. Komodo Health has the most complete all-payer claims picture for patient journey work. Definitive Healthcare has the best institutional/IDN data for hospital-centric go-to-market. ConcertAI has the most clinically rich, curated oncology dataset including molecular and imaging data.
Primary Pharma Use Cases
| Use Case | Best Fit | Runner-Up | Notes |
|---|---|---|---|
| Sales targeting / territory optimization | IQVIA | Komodo Health | Xponent + NBA algorithms remain field force standard |
| Market sizing & brand performance | IQVIA | Definitive Healthcare | NSD/NPA audits are non-negotiable for market share tracking |
| Patient journey mapping | Komodo Health | IQVIA | Closed, linkable lives give most complete longitudinal picture |
| HEOR / RWE generation | IQVIA / Komodo (tied) | ConcertAI (oncology) | IQVIA scale + regulatory acceptance; Komodo data completeness |
| Clinical trial optimization | ConcertAI | IQVIA | ACT platform and CARAai ahead of market |
| KOL / medical affairs targeting | IQVIA | Komodo Health | OneKey + publication data |
| Market access / payer analytics | IQVIA | Komodo Health | LAAD data and GTN platform are industry-embedded |
| Oncology-specific commercial launch | ConcertAI | Komodo Health | Precision GTM integrates EMR, claims, SDOH |
| Hospital/IDN intelligence | Definitive Healthcare | IQVIA | Definitive’s core franchise |
| Rare disease | Komodo Health | IQVIA | Complete patient journey across all payers is superior for rare disease |
Technology Approach
| Dimension | IQVIA | Komodo Health | Definitive Healthcare | ConcertAI |
|---|---|---|---|---|
| Delivery model | Hybrid: data licensing + SaaS + managed services | SaaS-first; enterprise subscription | SaaS platform (subscription) | SaaS (AI-native) + DaaS projects |
| AI approach | ML Next Best Action; Orchestrated Analytics; WhizAI conversational AI | Marmot AI (healthcare-native, auditable) | ML/AI segmentation layer | Deepest: CARAai multimodal, oncology LLMs, agentic AI, digital pathology |
| Self-service | Limited without account team | Strong — designed for analyst self-service | Moderate | Moderate for SaaS; expert-mediated for custom RWE |
| Implementation | 3-12 months typical | Weeks-to-months | Weeks-to-months | Varies by use case |
Revenue, Scale, and Financial Trajectory
| Metric | IQVIA | Komodo Health | Definitive Healthcare | ConcertAI |
|---|---|---|---|---|
| Revenue | $15.4B total; $6.16B TAS (2024) | ~$200M (2023 est.) | $241.5M (2025) | ~$200M (FY2023) |
| Employees | ~88,000 | ~600-800 est. | ~782 | 501-1,000 est. |
| Valuation | ~$45B+ (public) | $3.3B (2021 round) | ~$360M (private) | $1.9B (2022 round) |
| Revenue growth | +5.1% TAS (2024) | 50%+ ARR growth (2022); normalizing | -4.3% (2025); -6-9% projected (2026) | ~30% ARR growth (2023) |
| Profitability | Profitable; $3.68B adj. EBITDA | Not profitable | Profitable (29% adj. EBITDA margin) | Profitable; mid-teens EBITDA |
| Ownership | Public (NYSE: IQV) | Private (VC-backed) | Private (Advent International) | Private (VC-backed) |
The financial picture is starkest for Definitive Healthcare — two consecutive years of revenue decline with further decline projected. Advent’s PE ownership introduces questions about long-term product investment.
Competitive Moat
| Vendor | Primary Moat | Vulnerability |
|---|---|---|
| IQVIA | Data exclusivity + workflow lock-in: Xponent sourced from pharmacies under multi-decade relationships; OCE embedded in field rep workflow | Cost and complexity create dissatisfaction; AI challengers eating edges |
| Komodo Health | Closed, linkable patient database: fully integrated all-payer dataset took years and tens of millions to assemble | Dependent on third-party payer data access; Epic/Cerner building own RWD; no prescriber-level Rx audit |
| Definitive Healthcare | Institutional data depth: hospital profiles, IDN structures built over 15 years | Revenue trajectory; privatization uncertainty; IQVIA and Komodo closing gap |
| ConcertAI | CancerLinQ data + academic oncology network: independent of any single EMR, lab, or provider | Narrow therapeutic focus; no prescriber-level Rx data; not for general commercial analytics |
Pricing Models
| Vendor | Model | Typical Buyer |
|---|---|---|
| IQVIA | Data licensing + platform subscription + managed services; multi-year enterprise; high minimums | Top-30 pharma with dedicated analytics teams |
| Komodo Health | Enterprise SaaS subscription; $150K-$450K/yr cited per use case | Mid-to-large pharma, specialty biopharma |
| Definitive Healthcare | SaaS subscription; enterprise ARR threshold $17,500/customer | Life sciences, device, diversified healthcare |
| ConcertAI | SaaS + DaaS hybrid; 72% ARR; project-based for custom studies | Oncology-focused biopharma, clinical development |
Use Case Recommendations
When to Choose IQVIA
Choose when core need is field force optimization and prescriber-level Rx data at scale. If commercial operations runs on Xponent for territory management, call planning, NBA, and market share tracking — IQVIA is effectively non-optional. Same for global market analysis (77 countries via MIDAS) and market access (LAAD data, GTN platform embedded in most large pharma). Trade-off is cost and implementation burden.
Ideal buyer: Top-30 global pharma with dedicated commercial analytics, multiple brands, multi-country presence. IQVIA is table stakes, not a choice.
When to Choose Komodo Health
Choose when primary need is patient journey analysis, rare disease targeting, or non-oncology-specific RWE. Closed, linkable Healthcare Map is the best instrument for understanding full longitudinal patient journey across care settings. For specialty biopharma and rare disease launches where treatable population is small and maximum data completeness is needed, Komodo outperforms IQVIA’s sample-based projections. Marmot AI puts analysis within reach of teams without large data science resources.
Ideal buyer: Specialty or rare disease biopharma; HEOR and medical affairs teams; companies launching in oncology, immunology, neurology, or metabolic disease.
When to Choose Definitive Healthcare
Choose when go-to-market is hospital- and IDN-centric — device companies, specialty pharma selling into hospital formularies, institutional purchase-driven prescribing. Facility-level intelligence (IDN structures, decision-maker mapping, purchasing patterns) is genuinely superior.
Be cautious: Financial and strategic uncertainty from Advent privatization plus two years of revenue contraction warrant careful contract term diligence.
Ideal buyer: Medical device commercial teams; specialty pharma with significant institutional sales motion.
When to Choose ConcertAI
Choose when need is oncology clinical development, precision oncology RWE, or oncology-specific commercial intelligence with deep clinical context. Not a general-purpose commercial analytics platform. Provides curated, research-grade, multi-modal oncology data (EMR + genomic + imaging + pathology) for HEOR, biomarker analysis, trial design, and regulatory submissions. ACT platform for clinical trial acceleration (10-20 months shorter timelines) is genuinely differentiated.
Ideal buyer: Oncology and hematology biopharma with clinical development, medical affairs, and commercial teams operating in the same TA.
Verdict
The four platforms are not competing for the same budget. The most actionable framing is ecosystem, not choice.
IQVIA is infrastructure for any pharma company with a field force and branded prescription product. The evaluation question is not “whether to use IQVIA” but “how much of the broader platform to rely on versus supplement with point solutions.”
Komodo Health is the most compelling supplemental or replacement platform for patient-journey and RWE work. Its closed, linkable Healthcare Map is structurally superior to IQVIA’s sample-and-project approach for specialty and rare disease populations. With Marmot AI, offers faster path to research-grade patient insights.
Definitive Healthcare is the right answer for hospital/IDN-centric commercial models — and a questionable investment for everyone else given current financial trajectory. Teams with outpatient, prescriber-driven motions should evaluate carefully.
ConcertAI is the clear winner in oncology clinical development and building a compelling case in oncology-specific commercial analytics. Companies in solid tumor or hematology programs needing to unify clinical, genomic, and commercial data should evaluate ConcertAI as primary data infrastructure.
The honest procurement conclusion: a sophisticated large pharma company with an oncology portfolio likely needs IQVIA (Rx data, field force), Komodo (patient journey, specialty HEOR), and ConcertAI (clinical development, oncology launch analytics). Definitive Healthcare is most useful for significant institutional sales exposure. Treating these as mutually exclusive is a false choice.
Related Wiki Pages
Vendor Profiles
Category Pages
Concept Pages
- Specialty Drug Commercialization
- PE Consolidation in Pharma Services
- Patient Access Journey
Related Comparisons
- Market Access Consulting — IQVIA also appears as consulting vendor
- Hub Services Platforms — Hub vendors that consume data from these platforms
Frequently Asked Questions
What are the best pharma data analytics platforms?
The four dominant platforms are IQVIA (industry standard for prescriber-level Rx data and field force optimization, $15.4B revenue), Komodo Health (best for patient journey mapping with 330M+ patient Healthcare Map), Definitive Healthcare (strongest for hospital and IDN intelligence with 15M HCPs and 301K organizations), and ConcertAI (leading oncology-focused RWE platform with 5.5M curated oncology records). Most sophisticated pharma companies use multiple platforms rather than treating them as mutually exclusive.
How does IQVIA compare to Komodo Health?
IQVIA has the deepest prescriber-level prescription data through Xponent (93% of outpatient Rx) and global reach across 77 countries, making it effectively non-optional for companies with field forces. Komodo Health has the most complete all-payer claims picture with 330M+ patients and 160M closed linkable lives, making it superior for longitudinal patient journey analysis, rare disease targeting, and specialty HEOR. IQVIA excels at sales targeting and market sizing; Komodo excels at understanding complete patient journeys across care settings.
What is the best data platform for oncology pharma companies?
ConcertAI is the clear leader for oncology-specific clinical development and commercial analytics. Its CARAai platform includes 5.5M multi-modal oncology records from the CancerLinQ acquisition, oncology-tuned LLMs, digital pathology, and integration with Foundation Medicine covering nearly 500K clinico-genomic cancer patients. The ACT platform can shorten clinical trial timelines by 10-20 months. For general commercial analytics alongside oncology, companies typically combine ConcertAI with IQVIA for Rx data and Komodo Health for patient journey work.
How much do pharma data analytics platforms cost?
Pricing varies significantly by vendor and use case. IQVIA uses multi-year enterprise licensing with high minimums suited to top-30 pharma with dedicated analytics teams. Komodo Health charges enterprise SaaS subscriptions typically ranging from $150K-$450K per year per use case. Definitive Healthcare offers SaaS subscriptions with an average enterprise ARR threshold of $17,500 per customer. ConcertAI uses a hybrid SaaS plus data-as-a-service model with 72% recurring revenue and project-based pricing for custom studies.